Pages that link to "Q34156657"

The following pages link to Tolerability and safety aspects of mirtazapine (Q34156657):

Displaying 23 items.

• Mirtazapine to reduce methamphetamine use: a randomized controlled trial (Q24603456) (← links)
• Treatment of Progressive Multifocal Leukoencephalopathy With Mirtazapine. (Q30249052) (← links)
• Glycoprotein IIb/IIIa complex is the target in mirtazapine-induced immune thrombocytopenia (Q33347934) (← links)
• 'Doing the right thing': factors influencing GP prescribing of antidepressants and prescribed doses (Q33808307) (← links)
• A generalist's guide to treating patients with depression with an emphasis on using side effects to tailor antidepressant therapy (Q33884174) (← links)
• Pharmacologic advances in the systemic treatment of itch (Q36317067) (← links)
• Identifying predictive clinical characteristics of the treatment efficacy of mirtazapine monotherapy for major depressive disorder (Q37338064) (← links)
• A Review of the Literature of Mirtazapine in Co-Occurring Depression and an Alcohol Use Disorder (Q37738677) (← links)
• A review of the adverse effects and safety of noradrenergic antidepressants (Q38115737) (← links)
• Panic Attacks During Escalation of Mirtazapine (Q40621839) (← links)
• More evidence on additive antipsychotic effect of adjunctive mirtazapine in schizophrenia: an extension phase of a randomized controlled trial (Q42673319) (← links)
• Phase II trial of mirtazapine for cancer-related cachexia and anorexia (Q43272312) (← links)
• Mirtazapine for the treatment of hot flushes in breast cancer survivors: a prospective pilot trial. (Q44249143) (← links)
• Comparison of the effects of mirtazapine and fluoxetine in severely depressed patients (Q45255243) (← links)
• A randomized trial on the acute and steady-state effects of a new antidepressant, vortioxetine (Lu AA21004), on actual driving and cognition (Q45847558) (← links)
• Brain-derived neurotrophic factor gene polymorphisms and mirtazapine responses in Koreans with major depression. (Q45984035) (← links)
• Management of chemotherapy-induced side-effects (Q46518938) (← links)
• Effect of serotonin receptor 2A gene polymorphism on mirtazapine response in major depression (Q46722416) (← links)
• Changes of sleep architecture, spectral composition of sleep EEG, the nocturnal secretion of cortisol, ACTH, GH, prolactin, melatonin, ghrelin, and leptin, and the DEX-CRH test in depressed patients during treatment with mirtazapine (Q46764282) (← links)
• A suspicious bathtub death in a suicidal patient on mirtazapine (Q46959242) (← links)
• Genetic predictors of antidepressant side effects: a grouped candidate gene approach in the Genome-Based Therapeutic Drugs for Depression (GENDEP) study (Q48372657) (← links)
• Verbal memory performance during subchronic challenge with a selective serotonergic and a mixed action antidepressant (Q51978697) (← links)
• Paroxetine augmentation in patients with generalised social anxiety disorder, non-responsive to mirtazapine or placebo (Q87427205) (← links)